Drug intelligence / Profile preview

REVN-24

Development stage: Unknown
Lead developer: Chugai Pharmaceutical
Modality: Small Molecules
Administration: Intravenous

Overview

REVN-24 (also referred to as REVN24) is an in-house developed small molecule drug candidate from Chugai Pharmaceutical. It is currently in Phase 1 clinical development for the treatment of acute diseases and is administered intravenously. As of early 2026, the drug is categorized under 'Other Diseases' in the company's global pipeline, and specific information regarding its biological target or mechanism of action has not been publicly disclosed.

Beyond the preview

Go deeper on REVN-24.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REVN-24.

Explore the full profile